PER-104-03已完成1 期
RANDOMIZED STUDY OF PHASE III OF CARBOPLATIN, PACLITAXEL AND THORAXIC RADIOTHERAPY WITH OR WITHOUT TALIDOMIDE IN PATIENTS WITH CLINICAL STAGE III NSCLC
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),0 个研究点目标入组 0 人开始时间: 2004年2月6日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Newly diagnosed histological and confirmed non-small cell bronchogenic carcinoma.
- •Patients must have either unresectable Stage MIA disease or Stage MIB disease without significant pleural effusion. Unresectable.
排除标准
- •Los pacientes no deben estar embarazadas o amamantando debido a los conocidos efectos teratogenicos de la Thaidomida.
- •Las pacientes femeninas que tienen alguna posibilidad de quedar embarazadas deben tener un
- •prueba de embarazo realizada dentro de las 24 horas del comienzo de la thaidomida, semanalmente durante las primeras 4 semanas de tratamiento, y luego cada 4 semanas si los periodos de los pacientes son regulares o cada 2 semanas si no lo son. Las mujeres en edad fertil y los varones sexualmente activos deben usar dos metodos anticonceptivos aceptados y efectivos.
研究者
相似试验
进行中（未招募）
不适用
A RANDOMIZED PHASE II STUDY OF CARBOPLATIN AND PACLITAXEL +/- CETUXIMAB, IN ADVANCED AND/OR RECURRENT CERVICAL CANCER - Cetuximab in cervical cancerADVANCED AND/OR RECURRENT CERVICAL CANCERMedDRA version: 9.1Level: LLTClassification code 10008363Term: Cervix uteri cancer recurrentEUCTR2009-010099-74-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
进行中（未招募）
1 期
Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancerewly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancerEUCTR2014-005070-11-PLAbbVie Deutschland GmbH & Co. KG1,100
进行中（未招募）
1 期
Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancerEUCTR2014-005070-11-DKAbbVie Deutschland GmbH & Co. KG1,100
进行中（未招募）
1 期
Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancerewly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancerEUCTR2014-005070-11-ESAbbVie Deutschland GmbH & Co. KG1,100
进行中（未招募）
不适用
A PHASE II, RANDOMIZED STUDY OF CARBOPLATIN-GEMCITABINE PLUS CARBOPLATIN-PACLITAXEL VERSUS CARBOPLATIN-PACLITAXEL IN PLATINUM-SENSITIVE PATIENTS WITH RECURRENT OVARIAN CARCINOMA, PRIMARY PERITONEAL CARCINOMA OR FALLOPIAN TUBE CANCER.Ovarian Carcinoma (MedDRA 6.1, PT:10033128), Primary Peritoneal Carcinoma (MedDRA 6.1, PT:10052171) and Fallopian Tube Cancer (MedDRA 6.1, PT:10016180),MedDRA version: 6.1Level: PTClassification code 10033128EUCTR2004-000722-69-ESGrupo Español de Investigación en Cáncer de Ovario (GEICO)